Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes

What Was Tested

The paper reports a study of Exenatide, published as a randomized controlled trial.

AC2993 (synthetic exendin-4; exenatide) is a peptide that enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying.

AC2993 also promotes beta-cell proliferation and neogenesis in vitro and in animal models.

This study examines the activity and safety of subcutaneously injected AC2993 in patients with type 2 diabetes currently treated with diet and/or oral antidiabetic agents (OAAs).

Who Took Part

The study group was 109 patients.

PubMed indexes the participants as middle-aged adults, both men and women.

A total of 109 patients treated with diet and a sulfonylurea and/or metformin were enrolled in a blinded study.

How the Study Was Run

In design terms this was a randomized and placebo-controlled study.

Because people in this Exenatide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The comparison arm used a placebo, so changes seen with Exenatide could be set against what happens without it.

What Was Measured

Topics PubMed links to this paper include Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 2, Exenatide, Fructosamine, Glycated Hemoglobin and Heart Rate.

What This Means in Plain Language

The paper is a randomized and placebo-controlled study of Exenatide in 109 patients.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2003 (Diabetes care), a journal based in United States.

More context: the Exenatide compound page, all human trials.